Enhanced External Counterpulsation for the Treatment of Angina With Nonobstructive Coronary Artery Disease

Namrita D Ashokprabhu1, Jessie Fox2, Timothy D Henry1

  • 1Women's Heart Center, The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio; The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio.

PubMed

Insights

Enhanced external counterpulsation (EECP) effectively treats refractory angina in patients with nonobstructive coronary artery disease (ANOCA). This noninvasive therapy significantly improves angina class, exercise capacity, and quality of life, offering a valuable treatment option.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Noninvasive Cardiovascular Therapies

Background:

  • Angina and nonobstructive coronary artery disease (ANOCA) presents challenges due to limited treatment options and poor outcomes.
  • Enhanced external counterpulsation (EECP) is an established noninvasive therapy for refractory angina in obstructive coronary artery disease, but its role in ANOCA is less defined.

Purpose of the Study:

  • To assess the efficacy of EECP in patients suffering from refractory angina despite having nonobstructive coronary artery disease (ANOCA).
  • To evaluate the impact of EECP on Canadian Cardiovascular Society (CCS) angina class, exercise tolerance, and quality of life in ANOCA patients.

Main Methods:

  • A cohort of 101 patients with ANOCA and CCS class III/IV angina underwent a full course of EECP treatment.
  • Outcomes were measured by changes in CCS angina class, 6-minute walk test, Duke Activity Status Index (DASI), Seattle Angina Questionnaire 7 (SAQ7), and weekly anginal episodes pre- and post-treatment.

Main Results:

  • Significant improvements were observed in CCS angina class (3.4 to 2.4, p <0.001), 6-minute walk test (p <0.001), DASI (15.2 to 31.5, p <0.001), SAQ7 (p <0.001), and weekly anginal episodes (5.3 to 2.4, p <0.001).
  • Over 70% of patients experienced an improvement of at least one CCS angina class, with nearly 33% improving by two or more classes.

Conclusions:

  • EECP therapy demonstrates significant benefits for patients with ANOCA experiencing refractory angina.
  • The findings suggest EECP should be considered a valuable component of optimal medical therapy for this patient population, improving symptoms and functional capacity.

Related Concept Videos

Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
9
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
18
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
608
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
7
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
9